Charles River Laboratories (CRL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Charles River Laboratories (CRL) has a cash flow conversion efficiency ratio of 0.062x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($213.83 Million) by net assets ($3.45 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Charles River Laboratories - Cash Flow Conversion Efficiency Trend (1998–2024)
This chart illustrates how Charles River Laboratories's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Charles River Laboratories total liabilities for a breakdown of total debt and financial obligations.
Charles River Laboratories Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Charles River Laboratories ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sunny Optical Technology (Group) Company Limited
F:SXC
|
0.020x |
|
Western Alliance Bancorporation
NYSE:WAL
|
-0.009x |
|
NexGen Energy Ltd.
TO:NXE
|
-0.011x |
|
Vienna Insurance Group AG
VI:VIG
|
0.022x |
|
Companhia Paranaense de Energia - COPEL
NYSE:ELPC
|
0.006x |
|
National Aluminium Company Limited
NSE:NATIONALUM
|
0.137x |
|
NIBE Industrier AB (publ)
ST:NIBE-B
|
0.161x |
|
Xp Inc
NASDAQ:XP
|
0.520x |
Annual Cash Flow Conversion Efficiency for Charles River Laboratories (1998–2024)
The table below shows the annual cash flow conversion efficiency of Charles River Laboratories from 1998 to 2024. For the full company profile with market capitalisation and key ratios, see CRL company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $3.51 Billion | $734.58 Million | 0.209x | +12.03% |
| 2023-12-31 | $3.66 Billion | $683.90 Million | 0.187x | -8.80% |
| 2022-12-31 | $3.02 Billion | $619.64 Million | 0.205x | -30.18% |
| 2021-12-31 | $2.59 Billion | $760.80 Million | 0.294x | +15.12% |
| 2020-12-31 | $2.14 Billion | $546.58 Million | 0.255x | -11.65% |
| 2019-12-31 | $1.67 Billion | $480.94 Million | 0.289x | -12.45% |
| 2018-12-31 | $1.34 Billion | $441.14 Million | 0.330x | +10.90% |
| 2017-12-31 | $1.06 Billion | $316.26 Million | 0.297x | -14.93% |
| 2016-12-31 | $853.78 Million | $298.32 Million | 0.349x | -6.59% |
| 2015-12-31 | $765.56 Million | $286.36 Million | 0.374x | +4.94% |
| 2014-12-31 | $704.35 Million | $251.05 Million | 0.356x | +14.37% |
| 2013-12-31 | $664.66 Million | $207.14 Million | 0.312x | -9.58% |
| 2012-12-31 | $603.20 Million | $207.90 Million | 0.345x | -11.16% |
| 2011-12-31 | $529.14 Million | $205.28 Million | 0.388x | +58.09% |
| 2010-12-31 | $688.73 Million | $169.01 Million | 0.245x | +49.81% |
| 2009-12-31 | $1.37 Billion | $225.04 Million | 0.164x | -29.82% |
| 2008-12-31 | $1.20 Billion | $279.95 Million | 0.233x | +53.05% |
| 2007-12-31 | $1.86 Billion | $284.25 Million | 0.152x | +48.85% |
| 2006-12-31 | $1.60 Billion | $164.37 Million | 0.102x | -20.50% |
| 2005-12-31 | $1.84 Billion | $236.70 Million | 0.129x | +3.35% |
| 2004-12-31 | $1.48 Billion | $184.83 Million | 0.125x | -52.17% |
| 2003-12-31 | $474.80 Million | $123.77 Million | 0.261x | -26.68% |
| 2002-12-31 | $375.94 Million | $133.66 Million | 0.356x | +50.84% |
| 2001-12-31 | $302.50 Million | $71.30 Million | 0.236x | -9.08% |
| 2000-12-31 | $130.26 Million | $33.77 Million | 0.259x | +175.79% |
| 1999-12-31 | $-109.84 Million | $37.57 Million | -0.342x | -254.24% |
| 1998-12-31 | $168.56 Million | $37.38 Million | 0.222x | -- |
About Charles River Laboratories
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells roden… Read more